Hikma Pharmaceuticals Plc Stock Performance
| HKMPY Stock | USD 49.81 0.70 1.39% |
The company retains a Market Volatility (i.e., Beta) of 0.45, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Hikma Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Hikma Pharmaceuticals is expected to be smaller as well. At this point, Hikma Pharmaceuticals PLC has a negative expected return of -0.0243%. Please make sure to check out Hikma Pharmaceuticals' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Hikma Pharmaceuticals PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hikma Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Hikma Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 323 M | |
| Total Cashflows From Investing Activities | -238 M |
Hikma |
Hikma Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,100 in Hikma Pharmaceuticals PLC on September 13, 2024 and sell it today you would lose (119.00) from holding Hikma Pharmaceuticals PLC or give up 2.33% of portfolio value over 90 days. Hikma Pharmaceuticals PLC is currently producing negative expected returns and takes up 1.6013% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Hikma, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Hikma Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hikma Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Hikma Pharmaceuticals PLC, and traders can use it to determine the average amount a Hikma Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0152
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HKMPY |
Estimated Market Risk
| 1.6 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hikma Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hikma Pharmaceuticals by adding Hikma Pharmaceuticals to a well-diversified portfolio.
Hikma Pharmaceuticals Fundamentals Growth
Hikma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hikma Pharmaceuticals, and Hikma Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hikma Pink Sheet performance.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 110.13 M | |||
| Price To Earning | 10.10 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 2.55 B | |||
| EBITDA | 759 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 3.57 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Book Value Per Share | 19.77 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 2.99 X | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Current Asset | 1.57 B | |||
| Current Liabilities | 866 M | |||
About Hikma Pharmaceuticals Performance
Evaluating Hikma Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Hikma Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hikma Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.Things to note about Hikma Pharmaceuticals PLC performance evaluation
Checking the ongoing alerts about Hikma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hikma Pharmaceuticals PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hikma Pharmaceuticals generated a negative expected return over the last 90 days |
- Analyzing Hikma Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hikma Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Hikma Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hikma Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hikma Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hikma Pharmaceuticals' pink sheet. These opinions can provide insight into Hikma Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.